Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors during the central anxious system, conolidine modulates alternate molecular targets. A Science Improvements review found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By infl... https://johnv196cvk2.laowaiblog.com/profile